EP 3350202 A1 20180725 - IL-8-BINDING ANTIBODIES AND USES THEREOF
Title (en)
IL-8-BINDING ANTIBODIES AND USES THEREOF
Title (de)
IL-8-BINDENDE ANTIKÖRPER UND VERWENDUNGEN DAVON
Title (fr)
ANTICORPS DE LIAISON À L'IL-8 ET LEURS UTILISATIONS
Publication
Application
Priority
- JP 2015185254 A 20150918
- JP 2016003616 W 20160805
Abstract (en)
[origin: WO2017046994A1] One nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
IPC 8 full level
C07K 14/235 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01); C12N 15/62 (2006.01); C12P 21/02 (2006.01)
CPC (source: CN EP IL KR RU)
A61P 1/02 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 11/06 (2018.01 - EP); A61P 13/08 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 15/00 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 17/06 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 37/02 (2018.01 - EP); A61P 37/08 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07K 14/235 (2013.01 - RU); C07K 16/00 (2013.01 - RU); C07K 16/244 (2013.01 - CN EP IL KR); C07K 16/2866 (2013.01 - EP IL KR); C07K 16/36 (2013.01 - EP IL KR); C07K 16/40 (2013.01 - EP IL KR); C07K 16/42 (2013.01 - EP IL KR); C12N 15/62 (2013.01 - RU); C07K 2317/24 (2013.01 - EP IL); C07K 2317/31 (2013.01 - EP IL KR); C07K 2317/52 (2013.01 - CN EP IL KR); C07K 2317/526 (2013.01 - EP IL KR); C07K 2317/56 (2013.01 - CN); C07K 2317/565 (2013.01 - CN); C07K 2317/567 (2013.01 - EP IL KR); C07K 2317/72 (2013.01 - CN EP IL KR); C07K 2317/76 (2013.01 - EP IL KR); C07K 2317/92 (2013.01 - CN EP IL); C07K 2317/94 (2013.01 - CN EP IL)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2017046994 A1 20170323; AR 105634 A1 20171025; AU 2016323088 A1 20180222; AU 2016323088 B2 20201210; BR 112018002432 A2 20180918; CA 2993423 A1 20170323; CA 2993423 C 20240312; CL 2018000699 A1 20190208; CN 108271372 A 20180710; CN 108271372 B 20210709; CN 113372443 A 20210910; CO 2018004056 A2 20181130; CR 20180217 A 20180503; EP 3350202 A1 20180725; HK 1252615 A1 20190531; IL 258088 A 20180531; IL 258088 B1 20231001; IL 258088 B2 20240201; IL 285375 A 20210930; JP 2017536800 A 20171214; JP 2018085988 A 20180607; JP 2021168658 A 20211028; JP 2023164732 A 20231110; JP 6266164 B2 20180131; JP 6903561 B2 20210714; KR 101920175 B1 20181119; KR 102538745 B1 20230601; KR 20180006452 A 20180117; KR 20180125036 A 20181121; KR 20230079500 A 20230607; MA 42808 A 20180725; MX 2018003005 A 20180411; MX 2022008781 A 20220810; PE 20181336 A1 20180821; PH 12018500386 A1 20180903; RU 2018113505 A 20191018; RU 2018113505 A3 20200217; RU 2728430 C2 20200729; TW 201712032 A 20170401; TW 201823272 A 20180701; TW 202214688 A 20220416; TW 202342532 A 20231101; TW I621628 B 20180421; TW I751300 B 20220101; TW I814162 B 20230901; UA 120981 C2 20200310; ZA 201800536 B 20190731
DOCDB simple family (application)
JP 2016003616 W 20160805; AR P160102414 A 20160805; AU 2016323088 A 20160805; BR 112018002432 A 20160805; CA 2993423 A 20160805; CL 2018000699 A 20180316; CN 201680054135 A 20160805; CN 202110827885 A 20160805; CO 2018004056 A 20180416; CR 20180217 A 20160805; EP 16753718 A 20160805; HK 18111915 A 20180917; IL 25808818 A 20180313; IL 28537521 A 20210804; JP 2017242615 A 20171219; JP 2017508124 A 20160805; JP 2021103813 A 20210623; JP 2023159360 A 20230925; KR 20177037003 A 20160805; KR 20187032734 A 20160805; KR 20237017768 A 20160805; MA 42808 A 20160805; MX 2018003005 A 20160805; MX 2022008781 A 20180309; PE 2018000378 A 20160805; PH 12018500386 A 20180221; RU 2018113505 A 20160805; TW 105124915 A 20160805; TW 107108073 A 20160805; TW 110145197 A 20160805; TW 112123388 A 20160805; UA A201804018 A 20160805; ZA 201800536 A 20180125